POLISCOPE
Back to feed
Part ofFDA
FEDERALhearing transcript
High Impact

Senate Hearing on FDA User Fee Agreements

Original title: FDA USER FEE AGREEMENTS: IMPROVING MEDICAL PRODUCT REGULATION AND INNOVATION FOR PATIENTS, PART I

January 1, 2018

Track this bill to get notified when it advances a stage. One tap to stop, anytime.

The Frame

What this does

The hearing addresses the funding mechanism for the FDA, which directly impacts the speed and safety standards by which new medical drugs and devices are approved for public use.

Who is mentioned in the record

Potentially affected actors named in the source documents. Mention is not a position.

Food and Drug Administration (FDA)

The agency receives funding through user fee agreements to conduct regulatory reviews.

Medical product manufacturers

These companies pay user fees to the FDA as part of the product approval process.

Patients

Patients are affected by the speed and safety standards of the medical product approval process.

What changed

Last recorded activity January 1, 2018.

What's next

Next step not available in the current record.

Summary

This document is a transcript of a March 21, 2017, Senate committee hearing regarding the funding of the Food and Drug Administration (FDA) through . The hearing focused on how these fees support the regulation and approval process for medical drugs and devices to ensure they reach patients efficiently.

Key Facts

  • The hearing was held on March 21, 2017, by the Senate Committee on Health, Education, Labor, and Pensions.
  • The primary subject is the reauthorization and implementation of FDA User Fee Agreements for drugs and medical devices.
  • User fees are a funding source for the FDA to manage the regulatory process for medical products.
  • The hearing follows the passage of the 21st Century Cures Act, which aimed to accelerate the medical product approval process.
  • Witnesses included directors from the FDA's Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, and Center for Devices and Radiological Health.

Frequently Asked Questions

What are FDA User Fee Agreements?
These are agreements where companies that produce medical products pay fees to the FDA to help fund the agency's review process for those products.
Why is this hearing important for patients?
The funding levels determined by these agreements influence how quickly the FDA can review and approve new drugs and medical devices for patient use.

Why It Matters

The hearing addresses the funding mechanism for the FDA, which directly impacts the speed and safety standards by which new medical drugs and devices are approved for public use.

News Coverage

No news coverage found yet. Articles are indexed twice daily.

Sponsors

Discoveries

Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.

policy shift90% confidence

Post-Cures Act Implementation

The hearing explicitly links the FDA user fee process to the implementation of the 21st Century Cures Act, showing a legislative intent to tie funding to faster regulatory timelines.

Connected Entities

personPeter MarksDirector, Center for Biologics Evaluation and Research, FDAMap →
personJanet WoodcockDirector, Center for Drug Evaluation and Research, FDAMap →
personJeffrey E. ShurenDirector, Center for Devices and Radiological Health, FDAMap →
personLamar AlexanderChairman of the Senate Committee on Health, Education, Labor, and PensionsMap →
personPatty MurrayU.S. Senator from WashingtonMap →

Sources

Open source document

www.govinfo.gov

Analysis Score

0–100
  • Significance75
    How much this matters to a regular citizen
  • Controversy20
    Intensity of disagreement among stakeholders
  • Entertainment10
    Compellingness for a non-policy-wonk reader
  • Buzz15
    Current news / social attention level

Publisher tools

Share or embed this record

POLISCOPE publisher tools

Share or embed this record